The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.
Glenmark Pharmaceuticals Ltd on Tuesday said it has acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the US. The acquisition by the company's fully-owned subsidiary Glenmark Pharmaceuticals Inc, USA includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine, the company said in a statement. The company, however, did not disclose the financial details.
Glenmark Pharmaceuticals on Monday said its subsidiary Glenmark Pharmaceuticals SA has granted licence to Sanofi-aventis for developing drugs to treat chronic pain, for an initial payment of $20 million (about Rs 89 crore).
Glenmark Pharmaceuticals on Thursday said it will sell a 75 per cent stake in its subsidiary Glenmark Life Sciences to Nirma Ltd for Rs 5,651.5 crore.
It is the generic version of Teva Women's Health's Seasonale tablets
Glenmark Generics Inc USA, the subsidiary of Glenmark Generics Ltd has received nod for it's Hydrocortisone Butyrate Cream USP (0.1 per cent), abbreviated new drug approval from the United States Food and Drug Administration, Glenmark Pharmaceuticals said in a statement.
Glenmark Pharmaceuticals Inc, has signed a $27 million royalty deal with international healthcare investment fund Paul Capital Partners' Royalty Fund to finance the development of 16 dermatological products by the pharma major for the US market.
Glenmark Pharmaceuticals Ltd on Monday said its wholly-owned Swiss subsidiary
It can possibly be used to treat diseases like Arthritis and bowel disease.
Glenmark Pharmaceuticals, the Swiss subsidiary of Glenmark Pharmaceuticals, announced that it had successfully completed phase-I clinical trials for GRC 6211
As per the clinical trial protocol approved, 150 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care. Treatment duration is a maximum of 14 days and the total study duration will be a maximum for 28 days from randomisation.
Glenmark Pharmaceuticals (Glenmark), which reorganised its speciality and generics businesses recently, is looking to acquire a medium to large-scale speciality pharmaceutical company in the US.
Leading IT solution provider HCL Technologies Ltd has signed an agreement with Glenmark Pharmaceuticals Ltd for implementing its comprehensive drug labeling framework
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the company at its meeting held on February 14, 2003 has approved divesting its wholly-owned subsidiary Glenmark Laboratories Ltd, including sale of its manufacturing Plant
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
Glenmark Holdings SA, a wholly-owned Swiss subsidiary of Glenmark Pharmaceuticals, has signed a deal to acquire majority shareholding (less than 90 per cent) of Czech firm Medicamenta.
Glenmark Pharmaceuticals Ltd plans to divest its subsidiary Glenmark Laboratories Ltd to Mark Saldanha and his associates for Rs 350 million. It also plans to sell its manufacturing plant at Verna, Goa.
Domestic firms Aurobindo Pharma, Glenmark Pharmaceuticals and Natco Pharma have received US health regulator's approval to market their generic Rizatriptan Benzoate orally disintegrating tablets used for treating migraine in the American market.
Glenmark Generics Inc has settled the litigation pending between the company and GSK over patent actions concerning atovaquone and proguanil hydrochloride 250mg/100mg tablets, the generic version of GSK's Malarone tablets, Glenmark Pharma said.
In a bid to tap overseas market, Glenmark Pharmaceuticals Ltd's wholly owned US subsidiary has entered into a product development and marketing licence agreement with US-based K V Pharmaceutical Company
United States Food and Drug Administration (USFDA) has given final approval to Glenmark Generics Inc for their abbreviated new drug application (ANDA) for Norgestimate and Ethinyl Estradiol tablets USP in the strengths of 0.18 mg/0.035 mg, 0.215 mg/0.035 mg and 0.25/0.035 mg, the company said in a statement.
In a bid to tap the potential in Latin America, Glenmark Pharmaceuticals Ltd has acquired Brazil-based Laboratorios Klinger, ranked among the top 50 in that country, for $5.2 million.\n\n\n\n
Glenmark Pharmaceuticals has entered into an agreement with Shasun for joint development, filing and marketing of 12 generic drugs for the US market.
Under Glenmark's 2004 collaborative deal with Forest, the latter had the right to develop and sell the asthma and chronic obstructive pulmonary disorder drug in North America for an upfront payment and additional fees for each developmental milestone that could total $190 million in all. Upon commercialisation, Glenmark will retain the rights for selling the drug for the rest of the world while Forest will continue to sell the drug in North American.
Glenmark Pharmaceuticals Ltd has set up a wholly-owned subsidiary in the US to step up presence for the company's formulations and Active Pharmaceuticals Ingredients in that market.
Glenmark Pharmaceuticals on Monday announced its Swiss subsidiary has completed phase I clinical trials for GRC 6211, a pain reliever, and plans to launch the molecule in 2011.
According to analysts, Glenmark will have to pay a penalty of $16 million, following the latest verdict.
A sharp increase in interest costs has caused Glenmark Pharmaceuticals to post a consolidated net profit of Rs 80.9 crore for the second quarter, 31 percent lower than the Rs 117.3 crore for the previous corresponding quarter.
Pharmaceutical firm Glenmark said on Monday it had signed a supply and marketing agreement with Aspen USA for joint manufacturing and sales of three generic products in US.
Glenmark plans to start selling its anti-diarrhoea drug, Crofelemer, by the first-half of 2010 across the globe, except in North America, Europe, Japan and China, the company said. The confidence to sell the drug ahead of its rivals comes as the Crofelemer's original developer, Napo Pharmaceutical Inc, recently entered into a tie-up with a US-based drug maker, Salyx, for selling the drug in the US market, paving the way for Glenmark to sell it in the rest of the world.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances